

1 **Cell surface remodeling caused by the loss of TMEM30A in immune cells**

2

3 Cenk O. Gurdap^{1,#}, Franziska Ragaller^{1,#}, Marion Muller^{2,3,#}, Ellen Sjule¹, Taras Sych¹,
4 Linnea Blomén^{4,5}, Fredrik Thoren^{4,5}, Ilya Levental⁶, Kandice R. Levental⁶, Quentin
5 Sattentau^{2,7,*}, Erdinc Sezgin^{1,*}

6

7 ¹ Science for Life Laboratory, Department of Women's and Children's Health, Karolinska
8 Institutet, Tomtebodavägen 23, 17165 Solna, Sweden

9 ² The Max Delbrück Centre for Molecular Medicine, Campus Berlin-Buch, 13125 Berlin,
10 Germany.

11 ³ The Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Oxford
12 OX3 7FY, UK.

13 ⁴ Tumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research,
14 University of Gothenburg, Gothenburg 413 90, Sweden.

15 ⁵ Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine,
16 Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 90, Sweden.

17 ⁶ Molecular Physiology and Biological Physics, Center for Membrane and Cell Physiology,
18 School of Medicine, University of Virginia, Charlottesville, VA 22903

19 ⁷ Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.

20

21 **# These authors contributed equally**

22 *** Correspondence:**

23 erdinc.sezgin@ki.se

24 quentin.sattentau@path.ox.ac.uk

25

26 **Abstract**

27 Plasma membrane lipid asymmetry is tightly regulated and fundamental to mammalian
28 cell physiology. TMEM30A is the β -subunit of P4-ATPases, flippase enzymes that
29 maintain strict phosphatidylserine (PS) asymmetry by pumping it from the outer to the
30 cytosolic leaflet. Loss of TMEM30A function causes constitutive PS externalization and
31 has been implicated in diseases such as diffuse large B-cell lymphoma and tumour
32 immune evasion. Here, we systematically define the biophysical and molecular
33 consequences of TMEM30A deletion in transformed immune cells. Using live-cell lipid
34 reporters, membrane order probes and surface proteome mapping, we show that
35 TMEM30A-knockout cells display robust PS externalization accompanied by faster lateral
36 diffusion of membrane constituents and decreased plasma membrane order. Surface
37 proteome reorganization includes increased abundance of tetraspanins and CD47.
38 Further, TMEM30A loss triggers glycocalyx remodeling via ADAM10-dependent shedding
39 that removes major mucins, including CD43 and CD162. Together, these data reveal a
40 coordinated reorganization of lipids, glycans, and proteins upon TMEM30A loss that
41 mechanistically links flippase dysfunction to immune evasion, increased plasma
42 membrane dynamics and sensitization to anti-CD47 therapy. Moreover, Furthermore, our
43 study provides an integrated surfaceome framework that illuminates the relationship
44 between TMEM30A expression and clinical outcomes in cancer.

45

46 **Keywords:** TMEM30A/CDC50A, phosphatidylserine, lipid asymmetry, ADAM10, mucin
47 shedding, CD43, CD162, tetraspanins, CD47, molecular pixelation, membrane order,
48 lateral diffusion, immune evasion, DLBCL, fluorescence correlation spectroscopy,
49 Pro12A.

50

51

52

53

54

55

56

57

58

59 Introduction

60 Plasma membrane asymmetry is highly regulated and essential for numerous cellular
61 processes. Phosphatidylserine (PS) and phosphatidylethanolamine (PE) are typically
62 confined to the inner leaflet, while phosphatidylcholine and sphingomyelin are more
63 abundant on the outer leaflet^{1,2}. This asymmetric organization is crucial for, amongst other
64 functions, maintaining membrane curvature, enabling vesicle formation, and facilitating
65 signal transduction². Disruption of this asymmetry, such as via the externalization of PS,
66 can serve as a signal for immune recognition of apoptotic cells³. Additionally, homeostatic
67 lipid distribution supports the function of membrane proteins and receptors, ensuring
68 effective interaction and transport across the membrane³. Thus, membrane asymmetry is
69 fundamental to cell viability and cell-cell interactions. However, under certain
70 physiological and pathological conditions, such as during apoptosis, cell and platelet
71 activation, or cellular stress, PS is externalized to the outer leaflet³. In apoptosis, PS
72 exposure acts as an "eat-me" signal, recognized by phagocytes to facilitate the non-
73 inflammatory clearance of dying cells⁴. Moreover, externalized PS selectively activates "A
74 Disintegrin And Metalloprotease" (ADAM)-family metalloproteases^{5,6}, which can cleave
75 multiple substrates. Amongst these ADAM substrates are glycocalyx-embedded
76 transmembrane mucins, which when shed from the surface of apoptotic immune cells
77 increases recognition by phagocytes⁷. Additionally, PS can also play immunomodulatory
78 roles under other, non-apoptotic conditions⁸. These roles suggest a complex interplay
79 between PS and other surface molecules.

80 The strict maintenance of PS on the inner plasma membrane leaflet is mediated by
81 several enzymes. TMEM30A, also known as CDC50A, is an essential subunit of the P4-
82 ATPase phospholipid flippases, which maintain the asymmetric distribution of
83 phospholipids across cellular membranes⁹. Cells lacking functional TMEM30A show
84 constitutive PS flopping to the outer leaflet and are better at evading natural killer (NK)
85 cell-mediated cytotoxicity¹⁰. Relatedly, recurrent biallelic loss-of-function mutations in
86 TMEM30A were identified in diffuse large B-cell lymphoma (DLBCL), an aggressive
87 cancer, through genomic and transcriptomic analysis of patient samples from a
88 population-based registry¹¹. TMEM30A was suggested as a putative tumor suppressor,
89 potentially changing membrane organization in B cells. However, the role of TMEM30A
90 function in pathology is complicated, since TMEM30A loss has also been correlated with
91 favorable clinical outcomes in cancer treatment¹¹. TMEM30A-deficient cells had higher
92 uptake of chemotherapy drugs, and TMEM30A-deficient tumors exhibited increased
93 infiltration of tumor-associated macrophages and showed enhanced sensitivity to anti-
94 CD47 therapy¹¹. While these results suggest that loss of TMEM30A changes the surface
95 properties of cells, the biophysical and molecular changes on the cell surface, and how
96 they relate to tumor therapy, are not clear.

97 Here, we investigated the protein, carbohydrate and lipid remodeling taking place at the
98 plasma membrane of TMEM30A knock-out (TMEM30A-KO) transformed immune cell
99 lines. We show that TMEM30A-KO immune cells exhibit elevated PS on the outer leaflet,
100 faster diffusion of molecules in the plasma membrane and reduced plasma membrane
101 order. Surface protein mapping experiments showed that KO cells differentially regulate
102 several proteins including upregulation of members of the membrane protein-organizing
103 family of tetraspanins, and the checkpoint molecule CD47, and downregulate
104 transmembrane mucins CD43 and CD162. Using ADAM10 inhibitors, we confirm that
105 increased PS exposure correlates with ADAM10-dependent cleavage and loss of mucins
106 from the surface. Overall, our data reveal a major reorganization of lipids, carbohydrates
107 and proteins on the tumor immune cell surface upon loss of TMEM30A, illuminating the
108 physiological phenotypes of TMEM30A mutations, such as immune evasion, enhanced
109 membrane mobility, increased surface accessibility and better responses to anti-CD47
110 therapy.

111

112 **Results and Discussion**

113 To address how the loss of TMEM30A changes the cell surface with implications for
114 intercellular interactions and immune evasion, we initially characterized the plasma
115 membrane biophysical properties of two cell types in which TMEM30A was knocked out.

116 ***TMEM30A-KO cells expose PS on the cell surface***

117 PS externalization has previously been suggested as a protection mechanism against
118 immune cell killing¹². To this end, we first studied the PS exposure on two immortalized
119 immune cell lines: the Jurkat T cell line derived from an Acute Lymphoblastic Leukemia
120 (T-ALL) patient and the K562 line derived from a Chronic Myeloid Leukemia (CML)
121 patient. Wild-Type (WT) cells were compared with TMEM30A-KO for cell surface PS
122 expression using fluorescently tagged Lactadherin C2 domains (LactC2)^{13,14} followed by
123 confocal microscopy imaging and flow cytometric analysis. For flow cytometry analysis
124 the median fluorescence was derived for each sample using identical laser and detector
125 settings for WT and KO lines. The GMFI for WT was normalized to 1 and the KO signal
126 was represented as fold-change compared to WT. Both microscopy (**Fig. 1A**) and flow
127 cytometry (**Fig. 1B**) analysis showed that KO cells showed significantly higher LactC2
128 binding compared to WT, confirming that KO cells exhibit increased PS on the exoplasmic
129 leaflet¹⁰.

130 ***Loss of TMEM30A causes biophysical remodeling of the plasma membrane***


131 The composition and leaflet organization of lipids imparts functional membrane
132 biophysical properties. For example, high membrane order has been proposed as a
133 protection mechanism against immune cell killing¹⁵. Interestingly, loss of membrane

134 asymmetry through PS scrambling has been shown to reduce membrane ordering¹⁶.
135 Therefore, we tested whether loss of TMEM30A affects membrane order in the plasma
136 membrane. We first investigated membrane fluidity by measuring the diffusion of an outer
137 leaflet lipid tracer using fluorescence correlation spectroscopy (FCS). FCS measures the
138 diffusion of molecules by detecting the fluorescence fluctuations due to molecular
139 movement through the microscope observation volume. From the FCS curves, we
140 measured the diffusion coefficient, where higher values mean faster diffusion. The
141 diffusion of Abberior Star Red PEG-labelled DPPE lipid tracer was significantly faster in
142 KO cells compared to WT cells for both cell lines (**Fig. 1C**), suggesting that loss of
143 TMEM30A increases plasma membrane fluidity upon TMEM30A loss. This inference was
144 further supported by membrane order measurements by spectral imaging¹⁷ and spectral
145 flow cytometry¹⁸ using the environment sensitive probe Pro12A¹⁹ in (**Fig. 1D-1E**). Pro12A
146 reports membrane order by shifting its emission spectrum depending on the lipid
147 environment, which can be ratiometrically quantified as Generalized Polarization (GP)
148 value, where higher GP represents higher membrane order²⁰. KO cells showed
149 significantly less ordered membranes compared to WT cells in both Jurkat and K562
150 (colder colors in **Fig. 1D** and lower values in **Fig. 1E**). Of note, Pro12A specifically
151 measures membrane order in the outer leaflet¹⁹, hence these results confirm that the
152 outer leaflet of KO cells is more fluid than that of WT cells.

153 Regulation of the properties of two leaflet, e.g., whether they are independent from each
154 other, is largely unexplored. Therefore, we also set out to measure the properties of inner
155 leaflet. To do this, we used Halo-Tag protein reporters in combination with NileRed-Halo²¹.
156 These proteins localize the HaloTag to the inner leaflet of the plasma membrane, allowing
157 NileRed-Halo to specifically access this membrane leaflet. The lifetime of NileRed is
158 sensitive to the lipid environment, hence we could measure inner leaflet lipid order using
159 this approach. Interestingly, unlike the outer leaflet, we did not observe significant
160 differences between the inner leaflet membrane order of TMEM30A KO cells and WT cells
161 (Supplementary Figure S1). Our observation that TMEM30A-deficient cells maintain
162 normal inner-leaflet lipid order while exhibiting decreased outer-leaflet order potentially
163 suggests a striking asymmetry in how the plasma membrane responds to loss of
164 phospholipid flippase activity and how two leaflets are regulated in cells. The stability of
165 the inner leaflet implies that its biophysical properties are more tightly regulated likely
166 because it hosts most signaling lipids and proteins essential for cell survival, cytoskeletal
167 dynamics, and signal transduction. By preserving inner-leaflet order, TMEM30A KO cells
168 may maintain functional integrity of pathways that depend on precise lipid packing and
169 charge distribution, allowing them to continue proliferating despite substantial
170 outer-leaflet perturbations. In contrast, mechanisms disrupting both leaflets can
171 compromise inner-leaflet organization causing detrimental outcomes, including cell
172 death. These findings support the idea that not all forms of phosphatidylserine
173 externalization are biologically equivalent: TMEM30A loss selectively perturbs the outer

174 leaflet while sparing the signaling-competent inner leaflet, thereby preserving cellular
175 homeostasis even under conditions of chronic PS exposure.

176 Overall, these data show that the plasma membrane, specifically the outer leaflet, is
177 substantially reorganized in KO cells, explaining the previously reported increased
178 diffusivity of receptors on the cell surface¹¹. However, our observation does not align with
179 the immune evasion hypothesis¹² since the disordering of the membrane in KO cells
180 would be expected to sensitize, rather than protect, them from immune cell killing. To
181 explain this effect and further characterize the cell surface changes consequent to loss of
182 TMEM30A, we investigated the remodeling of specific plasma membrane proteins
183 implicated in immune regulation.



184

185 **Figure 1|** Biophysical properties of TMEM30A-KO cells. A) TMEM30A-KO Jurkat and K562 cells
186 are viable and exhibit PS+ puncta on the cell surface. PS is labelled with LactC2-Alexa647. B)
187 PS exposure was quantified in both cell types using flow cytometry, mean \pm SD. C) Diffusion of
188 Abberior Star Red-PEG-DPPE is faster in TMEM30A-KO cells compared to WT cells. Violin plots
189 showing the median and first and third quartiles. D) TMEM30A-KO cells have more fluid plasma
190 membranes compared to WT cells measured by Pro12A shown as GP map. E) Membrane order
191 (GP index) was quantified using spectral biophysical cytometry, mean \pm SD. Each data point is
192 an independent experiment (n=3) and p-values are calculated with a Mann-Whitney U test. Scale
193 bars are 10 μm .

194 **Loss of TMEM30A leads to major surface proteome remodeling**

195 The surface proteome (e.g., type, abundance and organization of the plasma membrane
196 proteins) is the central determinant of cell-cell interactions. Therefore, we tested whether

197 the loss of TMEM30A can remodel the surface proteome, with potential implications for
198 cancer, therapeutic responses, and immune evasion. Changes in membrane lipid
199 composition and the loss of lipid asymmetry can profoundly influence the repertoire and
200 function of surface proteins, since many of these rely on specific lipid interactions for
201 proper localization, conformation, and/or activity²². For instance, PS is known to interact
202 with and regulate the activity of ADAM family sheddases^{6,7,23,24} that cleave the
203 extracellular domains of numerous membrane proteins. Disruption of lipid asymmetry and
204 externalization of PS could therefore alter ADAM function and thereby reshape the
205 surface proteome. Moreover, loss of asymmetry can disrupt endocytic and exocytic
206 trafficking routes²⁵ potentially trapping certain proteins in endosomes or incorrectly
207 recycling them back to the surface. Finally, changing PS leaflet distribution can affect the
208 spatial arrangement of proteins including integrins, growth-factor receptors, and ion
209 channels^{26,27}. Thus, we set out to investigate how the absence of TMEM30A affects the
210 cell surface protein landscape.

211 We measured the remodeling of the surface proteome using the ‘molecular pixelation’
212 assay (**Fig. 2A**)²⁸. This assay works by labeling cell-surface proteins with antibody-
213 oligonucleotide conjugates (AOCs) and then converting their physical proximity into DNA
214 information that can be read by sequencing. After cells are fixed, DNA pixels (single-
215 stranded DNA molecules) are added, which hybridize with the AOCs and associate them
216 into local neighborhoods. By rolling circle amplification, the neighborhood information is
217 added to the AOCs and the oligos are subsequently amplified by PCR. This creates
218 DNA sequences containing barcodes to identify the unique AOCs, protein identity and
219 neighborhood membership. These DNA molecules are sequenced and computationally
220 reconstructed to quantify protein abundance and colocalization and to create interaction
221 networks of single cells with a spatial resolution of 280 nm, using standard next
222 generation sequencing methods.

223 Using antibodies specific for the selected proteins, we ran molecular pixelation analysis
224 in Jurkat cells and selected the proteins whose surface abundance was most affected by
225 TMEM30A KO (**Fig. 2B and C**). Transmembrane mucins such as CD162 and CD43 were
226 reduced significantly, while tetraspanin CD53 and integrin CD29 were significantly
227 increased. Interestingly, CD47, a negative regulator of phagocytosis and immune killing,
228 is also increased in KO cells. Besides abundance, polarity of the proteins (e.g.,
229 distribution of the proteins towards one side of the cell surface), a critical parameter for
230 immune cell function²⁹, also changed in KO cells. The tetraspanin CD53 was particularly
231 highly polarized in KO cells. Reduced polarization is often correlated with reduced
232 abundance as expected. When abundance and polarity were analyzed together (**Fig. 2D**),
233 mucins showed clear downregulation while tetraspanin CD53 and integrin CD29 showed
234 obvious upregulation in KO cells. CD47 was significantly different in abundance but not
235 in polarization, whereas the tetraspanin CD82 exhibited significantly different polarization


236 but not abundance. Finally, we compared protein colocalization differences between WT
237 and KO Jurkat cells (**Fig. 2E**) with purple indicating increased colocalization of protein
238 pairs in KO cells compared to WT cells. Tetraspanins CD53 increases in colocalization
239 with CD82, mucins like CD43 and adhesion-associated molecules such as CD102,
240 CD49D, CD29 and CD50. CD47 colocalization with CD2 also increased in KO cells. In
241 contrast, CD162 interacts less with CD47 and other mucins including CD43. These data
242 reveal that there is extensive surface proteome remodeling upon loss of TMEM30A.
243 Some proteins increase either in abundance (e.g., CD47) or clustering (e.g. CD82), or
244 increase in both abundance and clustering (e.g., CD53, CD29) while some decrease in
245 abundance and clustering (e.g., CD162, CD43).

246 Increase in CD47 expression, which relays an inhibitory signal upon interaction with
247 immune cells such as macrophages and NK cells³⁰, might contribute to the immune cell
248 evasion of cells with non-functional TMEM30. Moreover, this increases can account for
249 the susceptibility of TMEM30A-deficient DLBCL tumors to anti-CD47 therapies.
250 Changes in tetraspanin expression regulate interactions between surface proteins, and
251 interact specifically with ADAMs and modulate their enzyme activity and specificity³¹⁻³³.
252 For example, tetraspanin CD53 interacts with ADAM metalloproteases³⁴ and therefore
253 variation in the expression of tetraspanins such as CD53 and CD82 should be further
254 investigated in the context of ADAM activity. In this context, mucins were found to be
255 especially differentially regulated and a more detailed analysis on mucin alterations in
256 TMEM30A-KO cells was thus performed.

257

258 **Figure 2|** Jurkat surface proteome is dramatically reorganized by KO of TMEM30A. **A)** Scheme
259 of molecular pixelation experiment. **B)** Volcano plot for the abundance of proteins differentially
260 expressed on cell surface of WT vs. KO Jurkat cells. Orange dots indicate significantly up- or
261 downregulated proteins (adjusted p-value < 0.01). **C)** Proteins of differential abundance (log-fold
262 change >0.6) in WT vs. KO Jurkat cells. Color corresponds to log-fold change and size of the
263 bubbles indicates the adjusted p-value. **D)** Proteins that are significantly regulated in polarity
264 versus abundance. **E)** Differential colocalization map of relevant proteins (difference in
265 colocalization in KO compared to WT).

266




268 **Surface mucins are cleaved by ADAM10 in TMEM30A-KO cells**

269 Mucins are highly glycosylated glycoproteins on the cell surface that contribute heavily to
270 the glycocalyx, the interactive barrier between cells and their environments³⁵. This mucin
271 barrier is crucial for protecting cells from infection and damage, but also selectively
272 regulates interactions with other cells. Loss of mucins has been shown to affect
273 intercellular interaction with pathogens³⁶, immune cells and small molecules^{37–39}. During
274 apoptosis, the externalization of PS activates metalloprotease ADAM10 to cleave certain
275 substrates from the surface, including mucins^{6,7,23,24}.

276 Previous reports showed that TMEM30A-deficient cells are more accessible to small
277 molecule drugs and to phagocyte recognition¹¹ suggesting changes to the glycocalyx.
278 Taking these observations together, we tested whether loss of TMEM30A causes
279 ADAM10-dependent reorganization of the mucin barrier at the surface of immune cells.
280 To this end, we used flow cytometry to test the cell surface abundance of specific mucins
281 that were previously shown to be cleaved by ADAM10 in T-cells namely CD43, CD162
282 and MUC1. As a control, we also studied two mucins that are not cleaved by ADAM10,
283 namely CD45 and MUC24. Consistent with results from the molecular proximity assay,
284 we observed significantly reduced levels of CD43, CD162 and MUC1 in TMEM30A KO
285 cells, but no significant differences for CD45 and MUC24 (**Fig. 3A**). To confirm that this
286 decrease is due to ADAM10 activity rather than trafficking or transcriptional
287 downregulation, we incubated Jurkat cells with the ADAM10-specific inhibitor
288 (GI254023X, shortened to GI) or an ADAM10 and -17 inhibitor (GW 280264X, shortened
289 to GW) at a non-toxic concentration (10 μ M) for 24 h, and measured mucin loss. We
290 observed a complete reversion of the loss of ADAM10-cleaved mucins after treatment of
291 KO cells with the inhibitors, confirming the ADAM10-dependence of mucin shedding in
292 TMEM30A KOs (**Fig. 3B**). Of note, there was also a slight increase in the mucin signal in
293 WT cells (Supplementary Figure S2), suggesting a basal level of ADAM10 activity and
294 shedding of the extracellular domains of mucins even without externalized PS, which was
295 suggested recently²⁴ but may also correspond to constitutive low PS presence at the outer
296 leaflet of the WT plasma membrane (e.g., **Fig. 1A**).

297 These data reveal mucin shedding from the surface of TMEM30A KO cells in a PS- and
298 ADAM10-dependent manner. Reduced mucin abundance implies disruption of the mucin
299 barrier and increased accessibility of cells to external interactions and stimuli.

300 **Figure 3| Mucin profiling in TMEM30A-KO Jurkat cells. A)** Flow cytometry analysis of mucin
301 abundance on cell surface of TMEM30A-KO Jurkat cells. Data expressed as violin plots of mean
302 fluorescence intensity. **B)** Inhibition of mucin shedding shown by flow cytometry analysis of mucins
303 in KO cells treated with ADAM10 inhibitor (GI) or an ADAM10/17 inhibitor (GW). Data points
304 represent means of independent experiment; p-values calculated using RM one-way ANOVA test
305 (n=5 independent experiments).



306

307

308 Conclusion

309 TMEM30A-KO immune cells display robust PS externalization, as confirmed by LactC2-
310 based flow microscopy and cytometry indicating loss of membrane asymmetry. This lipid
311 redistribution triggers substantial biophysical remodeling of the plasma membrane: KO
312 cells exhibit significantly increased membrane fluidity, demonstrated by faster diffusion of
313 a lipid tracer in FCS measurements, and markedly decreased membrane order as
314 quantified by Pro12A spectral imaging and spectral flow cytometry. To determine whether
315 these changes extend to the protein landscape, we profiled the surface proteome using
316 molecular pixelation and found extensive remodeling, including strong downregulation of
317 CD162 and CD43 mucins and upregulation of tetraspanins (e.g. CD53), integrin CD29,
318 and the immune checkpoint protein CD47. In addition to altered abundance, protein
319 polarity and colocalization networks were reorganized, with increased clustering of CD53
320 and altered interactions involving CD47. Mechanistically, we demonstrated that mucin
321 loss was driven predominantly by ADAM10-dependent shedding. Together, these findings
322 reveal that TMEM30A loss induces a coordinated remodeling of surface lipids and
323 proteins, altering membrane biophysics and driving loss of otherwise highly expressed
324 membrane mucins.

325 Our results provide a mechanistic framework that help to explain why loss-of-function
326 TMEM30A mutations - despite being tumor-promoting - are consistently associated with
327 improved therapeutic responses, including enhanced sensitivity to chemotherapy and
328 superior outcomes with anti-CD47 immunotherapy. We show that loss of TMEM30A leads
329 to constitutive PS exposure on the outer membrane activating ADAM10-dependent
330 shedding of major surface mucins, disintegrating the dense glycocalyx barrier that
331 normally restricts drug penetration and shields tumor cells from immune engagement.

332 ADAM10-mediated loss of mucins decreases glycocalyx density thereby increasing
333 surface accessibility, offering a possible explanation for the previously reported
334 heightened uptake of chemotherapeutic agents in TMEM30A-deficient lymphomas. In
335 parallel, we find that TMEM30A-KO cells upregulate CD47 on their surface, creating an
336 expanded and more exposed “don’t-eat-me” checkpoint landscape. This molecular
337 reorganization makes CD47 more available for antibody binding, thereby theoretically
338 increasing tumor susceptibility to CD47-blocking therapies. Together, these findings may
339 resolve the clinical paradox: although loss-of function TMEM30A mutations may facilitate
340 oncogenesis, the resulting surfaceome remodeling, loss of the mucin barrier and
341 increased CD47 presentation, renders tumor cells more penetrable to drugs and more
342 responsive to immunotherapy. Therefore, this highlights the importance of revealing the
343 surface architecture of diseased cells to develop better therapies against them.

344 The increased B-cell receptor (BCR) mobility reported in TMEM30A-deficient tumors
345 could also be explained by our biophysical data. By demonstrating that TMEM30A loss
346 increases lateral diffusion and reduces membrane order of the outer leaflet, we provide a
347 direct physical basis for faster BCR movement on the cell surface that was reported
348 previously¹¹. In membranes, higher fluidity accelerates receptor encounters with
349 coreceptors and kinases, lowers the energetic barrier for nano-cluster formation, and
350 shortens the time to productive signaling assemblies⁴⁰. Thus, the disordering of the lipid
351 bilayer that is driven by PS externalization and consequent remodeling creates a
352 membrane environment that is more permissive to BCR diffusion, clustering, and
353 activation. In practical terms, this means TMEM30A-deficient B cells are intrinsically more
354 prone to initiate and sustain signaling due to diffusion-controlled interactions in the plasma
355 membrane, mechanistically aligning our measurements with the observed increase in
356 BCR mobility and signaling propensity in TMEM30A-mutant tumors.

357 Strong negative surface charge, high membrane order, a thick glycocalyx, and the
358 presence of inhibitory ligands are classically associated with immune evasion.
359 TMEM30A-deficient cells were previously reported to evade NK cell recognition by
360 triggering inhibitory TIM-3 receptors on NK cells. We extend these findings and show that
361 TMEM30A-KO cells display a more complex phenotype and exhibit two features
362 consistent with reduced susceptibility to NK-cell-mediated killing: pronounced
363 PS-dependent surface negativity and a marked upregulation of CD47, which strengthens
364 the “don’t-kill-me” inhibitory signal. However, other hallmarks typically linked to immune
365 resistance such as a highly ordered membrane and a thick, mucin-rich glycocalyx are
366 diminished rather than enhanced in KO cells. Our data show substantial mucin shedding
367 and membrane disordering, which should, in principle, increase accessibility to immune
368 cells. This apparent contradiction highlights that immune recognition is a multi-parametric
369 process shaped by the integrated contributions of many surface cues. It is plausible that
370 increased surface accessibility (due to the loss of mucins), combined with elevated CD47

371 expression, may actually amplify the functional engagement of CD47 with NK-cell
372 receptors, thereby strengthening the inhibitory signal despite a thinner glycocalyx and a
373 more fluid membrane.

374 Finally, our surfaceome mapping reveals extensive remodeling of protein abundance,
375 clustering, and colocalization networks, suggesting that additional organizational features
376 beyond individual markers critically shape immune cell-target cell interactions. Together,
377 these findings suggest that clinically relevant TMEM30A phenotypes might arise from a
378 complex interplay of lipid, protein, and glycocalyx changes, underscoring the need for
379 future studies to dissect how these parameters collectively modulate immune synapse
380 formation and cytotoxic responses.

381

382 **Materials and Methods**

383 *Cells*

384 Wild type and KO cells were described in detail in ref ¹⁰.

385 *Spectral imaging and spectral flow cytometry*

386 Spectral imaging of cells was performed as described in the protocol in ref ¹⁷.

387 PS measurement with LactC2 labeling: Cells seeded two days prior were harvested,
388 counted, and distributed into Eppendorf tubes at a density of 300,000 cells per 1 mL RPMI
389 medium. PS exposure was assessed using Bovine Lactadherin–Alexa Fluor 647
390 (PROLYTIX) and analyzed by flow cytometry. A total of 2 μ L of 83 μ g/mL dye was added
391 to each sample and incubated for 15 minutes at room temperature (RT). Cells were then
392 washed twice with PBS and finally resuspended in 200 μ L PBS before transfer to flow
393 cytometry tubes. Data acquisition was performed using 640 nm excitation (red laser) and
394 emission detection at 670–688 nm (center 670 nm, 18 nm bandwidth; R2 channel).
395 Analysis was conducted in FCS Express. The median autofluorescence signal from
396 unlabelled cells was subtracted from labelled samples. Median fluorescence intensities
397 were then used to calculate fold changes between WT and KO cells.

398 Membrane order with Pro12A labeling: 300,000 cells per sample were prepared as
399 described above and washed twice with PBS. Cells were labelled with 0.4 μ L of 200 μ M
400 Pro12A dye for 1 minute at RT immediately prior to acquisition. Flow cytometric analysis
401 was performed using 405 nm excitation (violet laser). Emission was collected at 420–435
402 nm (center 428 nm, 15 nm bandwidth; V1 channel) and 533–550 nm (center 542 nm, 17
403 nm bandwidth; V7 channel). Membrane order was quantified by calculating the
404 generalized polarization (GP) value using V1 and V7 channels. Details of gating strategy,
405 acquisition parameters, and data analysis are provided in ref¹⁸.

406 *Fluorescence Correlation spectroscopy*

407 Diffusion of Abberior Star Red-PEG-DPPE (Abberior) was measured using Fluorescence
408 Correlation Spectroscopy (FCS). Cultured cells were collected, the culture medium was
409 replaced with Leibovitz's L-15 serum-free medium and supplemented with 50 nM of
410 Abberior Star Red-PEG-DPPE. A Zeiss LSM 780 microscope with 40 × 1.2 NA water
411 immersion objective was used for FCS. A 633 nm He-Ne laser was used for excitation.
412 The laser power was set to 1% of the total laser power, corresponding to 20 μW. The
413 emission detection was done with GaAsP spectral detector in the range of 650–700 nm.

414 Due to movement of cell membrane, the so-called “scanning FCS”⁴¹ modality was chosen
415 to acquire data. Briefly, the line scan of 20 – 40 pixels was performed 50 000 times across
416 the plasma membrane in the equatorial plane of the cell. Furthermore, to account for the
417 cell movement, from every line scan the point with highest fluorescence intensity was
418 chosen to represent this time point. The resulting trace was further correlated and fitted.

419 FCS fitting and diffusion coefficient calculation was performed using the home-made
420 python based program Py-Profiler⁴². Curves were fitted with the following three-
421 dimensional diffusion model:

$$G(\tau) = \frac{1}{\langle N \rangle} \left(1 + \frac{\tau}{\tau_D}\right)^{-1} \left(1 + \frac{\tau}{AR^2 * \tau_D}\right)^{\frac{1}{2}}$$

422

423 Where $G(\tau)$ is a correlation function, τ stands for delay time, τ_D – for diffusion time, AR –
424 for aspect ratio of the focal volume and $\langle N \rangle$ - for an average number of molecules within
425 the focal volume.

426 Calibration was performed using 10 nM solution of Alexa467(ThermoFisher) in pure
427 water. Diffusion was calculated from the diffusion time using the following expression:

$$D = \frac{\omega^2}{8 \ln 2 \tau_D}$$

428

429 Where D is a diffusion coefficient, ω^2 stands for full width at half maximum of focus point
430 spread function, τ_D – for diffusion time. The trace extraction, correlation and fitting were
431 performed using home-made open-source software called “Py_profiler”. The release with
432 the sFCS functionality is available here:

433 https://github.com/taras-sych/Single-particle-profiler/tree/sFCS_Release_v1.0

434

435 *Inner Leaflet analysis with NileRed fluorescence lifetime*

436 2x10⁶ Jurkat T cells (WT and KO) were transfected with SH4-HaloTag or GG-HaloTag.
437 SH4-Halo is the N-terminal sequence of Lyn that codes for the myristol- and palmitoyl-
438 acylation sites with a C-terminal HaloTag. GG-HaloTag is the C-terminal sequence of K-

439 ras, which codes for the fatty acylation site and polybasic region. An N-terminal HaloTag
440 was appended to this sequence. Both probes localize to the inner leaflet of the plasma
441 membrane. 24 hr after transfection, the cells were washed two times with Tyrode's Buffer
442 (25 mM HEPES, 150 mM NaCl, 5 mM KCl, 5.4 mM glucose, 1 mM CaCl₂, 0.4 mM MgCl₂,
443 pH 7.2) and incubated with 200nM NR12-Halo (kindly provided by Andrey Klymchenko,
444 University of Strasbourg) in Tyrode's Buffer for 30 min at 37C. The cells were washed two
445 more times in complete medium for 10 min at 37C and imaged immediately using a Leica
446 SP8 confocal microscope with a 63x water immersion objective. FLIM images were
447 obtained with 485 nm excitation and emission from 550–800 nm and fit using Leica LAS
448 n-exponential deconvolution with two lifetimes. We report the intensity-weighted mean
449 lifetime value.

450

451 *Proxiome analysis*

452 Surface proteome mapping was performed using the molecular pixelation assay (MPX)
453 by Pixelgen Technologies²⁸. The Jurkat T WT cells or TMEM30A KO cells processing and
454 subsequent NGS sequencing of the DNA libraries were performed according to the
455 instructions provided in the MPX v2 User Manual (v2.00) by Pixelgen Technologies.
456 Subsequent data analysis including the pixelator pipeline, quality control, abundance
457 normalization, data integration, cell annotation as well as differential abundance, polarity
458 and colocalization analysis was performed according to the tutorials by Pixelgen
459 Technologies. Briefly, Cells were processed using the Pixelgen Single Cell Spatial
460 Proteomics Kit (Pixelgen Technologies, PXGIMM001) following the manufacturer's
461 protocol and recommended reagents (REF). Briefly, cells were thawed, washed, counted,
462 and fixed with 1% PFA (Electron Microscopy Sciences, 15710). After blocking, each
463 sample was divided into duplicates and stained with an 80-plex oligo-conjugated antibody
464 panel, then stabilized using a secondary antibody. From each replicate, 20,000 stained
465 cells were subjected to Molecular Pixelation. Molecular Pixels A were added first, followed
466 by a gap-fill reaction and subsequent removal of Pixel A. Molecular Pixels B were then
467 added and a second gap-fill reaction was performed. The cells were counted, and 1,000
468 cells from each replicate were processed with exonuclease treatment and indexing PCR.
469 The resulting PCR products were pooled and purified using AMPure XP beads (Beckman-
470 Coulter, A63881). Product purity was confirmed by gel electrophoresis on a TBE gel. The
471 purified libraries were spiked with 15% PhiX (Illumina, FC-110-3001) and sequenced
472 using paired-end sequencing (read 1: 28 cycles; read 2: 66 cycles; i7 index: 8 cycles; i5
473 index: 8 cycles) on an Illumina NextSeq 2000 system (donors 1 and 2: P3 flow cell; donor
474 3: P2 flow cell). Further analysis on cell subsets are shown in Supplementary Figure 3.

475 *Metalloprotease inhibitor treatment of Jurkat WT and TMEM30-KO*

476 For metalloprotease inhibitor experiments, WT and TMEM30-KO Jurkat at 4×10^5
477 cells/well of a U-bottomed 96 well plate in 200 μ L RPMI/10% FBS were treated with either
478 GI or GW at 10 μ M overnight at 37°C/5% CO₂. Cells were centrifuged for 5 min at
479 400 x g at room temperature and resuspended in FACS buffer for subsequent antibody
480 labeling.

481 *Flow cytometry for mucin analysis*

482 WT and TMEM30-KO Jurkat were plated at 4×10^5 cells/well of a U-bottomed 96 well
483 plate in 50 μ L 1 x annexin-V binding buffer (BD Biosciences 556454) for 20 min at room
484 temperature, containing the following antibodies: anti-human CD43-PE clone 10G7
485 (Biolegend 343204) at 4 μ g/mL; anti-human CD45-PE (MEM-28, Abcam ab134202) used
486 at 1:100; anti-human MUC1-PE clone 16 A (Biolegend 355604) used at 4 μ g/mL; anti-
487 human MUC24-PE clone 67D2 (Biolegend 324808) used at 0.5 μ g/mL; anti-human
488 PSGL-1-PE clone TC2 (Invitrogen A15789) used at 1:100, CD62L-PE clone DREG-26
489 (BD Biosciences 555544) used at 1 μ g/mL; annexin-V-FITC (Biolegend 640906) used at
490 0.9 μ g/mL. All antibody labeling was done in conjunction with the corresponding
491 concentration-matched isotype control antibody. After labeling, cells were washed 2 x with
492 annexin-V binding buffer, centrifuged for 5 min at 400 x g, and resuspended in 2 %
493 paraformaldehyde (Sigma-Aldrich 158127) for 15 min. After washing, cells were
494 resuspended in annexin-V binding buffer and analyzed by flow cytometry using a
495 Symphony A3 flow cytometer (BD Biosciences) and data processed using the FlowJo-
496 V10 software (FlowJo, LLC). Gating on the relevant cell population was set according to
497 Forward Scatter (FSC) and Side Scatter (SSC) before doublet exclusion.

498 **Conflict of Interest**

499 Authors declare no conflict of interest.

500 **Data Availability**

501 All data will be available in FigShare upon publication.

502 **Author Contributions**

503 All authors performed the experiments. ES and CG performed microscopy and flow
504 cytometry analyses. FR performed molecular pixelation experiments. LK and FT created
505 the KO cell lines. MM performed flow cytometry for mucin expression analysis. IL and
506 KRL performed leaflet specific biophysical experiments. ES, QS, IL, KRL and FT
507 supervised the team and provided funding. All authors contributed to manuscript writing
508 and editing.

509 **Acknowledgements**

510 ES has been supported by Swedish Research Council Grants (grant no. 2020-02682,
511 2024-02993 and 2024-00289), Wellcome Leap's Dynamic Resilience Program (jointly

512 funded by Temasek Trust), Karolinska Institutet (2024-03250; 2024-03341; 2022-00803;
513 2020-00997), Cancer Research KI (2024-03488), Human Frontier Science Program
514 (RGP0025/2022), Longevity Impetus Grant from Norn Group, Hevolution Foundation and
515 Rosenkranz Foundation. ES is an EMBO Young Investigator (YIP-2025). COG was
516 supported by Karolinska Institutet Doctoral funding (KID, 2022-00803). We thank the
517 SciLifeLab Advanced Light Microscopy facility and National Microscopy Infrastructure
518 (VR-RFI 2016-00968) for their support on imaging

519

520 **References**

- 521 1. Verkleij, A. J. *et al.* The asymmetric distribution of phospholipids in the human red
522 cell membrane. A combined study using phospholipases and freeze-etch electron
523 microscopy. *Biochim Biophys Acta* **323**, 178–193 (1973).
- 524 2. Lorent, J. *et al.* The Molecular and Structural Asymmetry of the Plasma Membrane.
525 *Nature Chemical Biology* 698837 (2020) doi:10.1101/698837.
- 526 3. Sakuragi, T. & Nagata, S. Regulation of phospholipid distribution in the lipid bilayer
527 by flippases and scramblases. *Nat Rev Mol Cell Biol* **24**, 576–596 (2023).
- 528 4. Nagata, S., Suzuki, J., Segawa, K. & Fujii, T. Exposure of phosphatidylserine on the
529 cell surface. *Cell Death Differ* **23**, 952–961 (2016).
- 530 5. Sommer, A. *et al.* Phosphatidylserine exposure is required for ADAM17 sheddase
531 function. *Nat Commun* **7**, 11523 (2016).
- 532 6. Bleibaum, F. *et al.* ADAM10 sheddase activation is controlled by cell membrane
533 asymmetry. *J Mol Cell Biol* **11**, 979–993 (2019).
- 534 7. Drexhage, L. Z. *et al.* Apoptosis-mediated ADAM10 activation removes a mucin
535 barrier promoting T cell efferocytosis. *Nat Commun* **15**, 541 (2024).
- 536 8. Birge, R. B. *et al.* Phosphatidylserine is a global immunosuppressive signal in
537 efferocytosis, infectious disease, and cancer. *Cell Death Differ* **23**, 962–978 (2016).

- 538 9. Li, J., Zhao, Y. & Wang, N. Physiological and Pathological Functions of TMEM30A:
539 An Essential Subunit of P4-ATPase Phospholipid Flippases. *Journal of Lipids* **2023**,
540 4625567 (2023).
- 541 10. Kristenson, L. *et al.* Deletion of the TMEM30A gene enables leukemic cell evasion of
542 NK cell cytotoxicity. *Proc Natl Acad Sci U S A* **121**, e2316447121 (2024).
- 543 11. Ennishi, D. *et al.* TMEM30A loss-of-function mutations drive lymphomagenesis and
544 confer therapeutically exploitable vulnerability in B-cell lymphoma. *Nat Med* **26**, 577–
545 588 (2020).
- 546 12. Rudd-Schmidt, J. A. *et al.* Lipid order and charge protect killer T cells from
547 accidental death. *Nat Commun* **10**, 5396 (2019).
- 548 13. Shi, J. *et al.* Lactadherin detects early phosphatidylserine exposure on immortalized
549 leukemia cells undergoing programmed cell death. *Cytometry A* **69**, 1193–1201
550 (2006).
- 551 14. Hu, T., Shi, J., Jiao, X., Zhou, J. & Yin, X. Measurement of annexin V uptake and
552 lactadherin labeling for the quantification of apoptosis in adherent Tca8113 and
553 ACC-2 cells. *Braz J Med Biol Res* **41**, 750–757 (2008).
- 554 15. Li, Y. & Orange, J. S. Degranulation enhances presynaptic membrane packing,
555 which protects NK cells from perforin-mediated autolysis. *PLOS Biology* **19**,
556 e3001328 (2021).
- 557 16. Doktorova, M. *et al.* Cell membranes sustain phospholipid imbalance via cholesterol
558 asymmetry. *Cell* **188**, 2586-2602.e24 (2025).
- 559 17. Carravilla, P. *et al.* Measuring plasma membrane fluidity using confocal microscopy.
560 *Nat Protoc* **20**, 1976–2004 (2025).

- 561 18. Andronico, L. A. *et al.* High-throughput analysis of membrane fluidity unveils a
562 hidden dimension in immune cell states. 2024.01.15.575649 Preprint at
563 <https://doi.org/10.1101/2024.01.15.575649> (2024).
- 564 19. Danylchuk, D. I., Sezgin, E., Chabert, P. & Klymchenko, A. S. Redesigning
565 Solvatochromic Probe Laurdan for Imaging Lipid Order Selectively in Cell Plasma
566 Membranes. *Anal. Chem.* **92**, 14798–14805 (2020).
- 567 20. Parasassi, T., De Stasio, G., Ravagnan, G., Rusch, R. M. & Gratton, E. Quantitation
568 of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan
569 fluorescence. *Biophysical Journal* **60**, 179–189 (1991).
- 570 21. Pelletier, R. *et al.* Genetic Targeting of Solvatochromic Dyes for Probing Nanoscale
571 Environments of Proteins in Organelles. *Anal. Chem.* **95**, 8512–8521 (2023).
- 572 22. Levental, I. & Lyman, E. Regulation of membrane protein structure and function by
573 their lipid nano-environment. *Nat Rev Mol Cell Biol* **24**, 107–122 (2023).
- 574 23. Seidel, J. *et al.* Role of ADAM10 and ADAM17 in Regulating CD137 Function. *Int J*
575 *Mol Sci* **22**, 2730 (2021).
- 576 24. Schahl, A. *et al.* Lipid-facilitated opening of the ADAM10 sheddase revealed by
577 enhanced sampling simulations. 2025.08.17.670722 Preprint at
578 <https://doi.org/10.1101/2025.08.17.670722> (2025).
- 579 25. Caputo, M. *et al.* Lipid asymmetry and membrane trafficking: Transbilayer
580 distribution of structural phospholipids as regulators of exocytosis and endocytosis.
581 *J Biol Chem* **301**, 110441 (2025).

- 582 26. Scott, H. L., Heberle, F. A., Katsaras, J. & Barrera, F. N. Phosphatidylserine
583 Asymmetry Promotes the Membrane Insertion of a Transmembrane Helix. *Biophys J*
584 **116**, 1495–1506 (2019).
- 585 27. Pabst, G. & Keller, S. Exploring membrane asymmetry and its effects on membrane
586 proteins. *Trends in Biochemical Sciences* **49**, 333–345 (2024).
- 587 28. Karlsson, F. *et al.* Molecular pixelation: spatial proteomics of single cells by
588 sequencing. *Nat Methods* **21**, 1044–1052 (2024).
- 589 29. Rudnicka, D. *et al.* Rituximab causes a polarization of B cells that augments its
590 therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.
591 *Blood* **121**, 4694–702 (2013).
- 592 30. Deuse, T. *et al.* The SIRP α -CD47 immune checkpoint in NK cells. *J Exp Med* **218**,
593 e20200839 (2021).
- 594 31. Lipper, C. H., Egan, E. D., Gabriel, K.-H. & Blacklow, S. C. Structural basis for
595 membrane-proximal proteolysis of substrates by ADAM10. *Cell* **186**, 3632-3641.e10
596 (2023).
- 597 32. Haining, E. J. *et al.* The TspanC8 Subgroup of Tetraspanins Interacts with A
598 Disintegrin and Metalloprotease 10 (ADAM10) and Regulates Its Maturation and
599 Cell Surface Expression *. *Journal of Biological Chemistry* **287**, 39753–39765
600 (2012).
- 601 33. Seipold, L. *et al.* In vivo regulation of the A disintegrin and metalloproteinase 10
602 (ADAM10) by the tetraspanin 15. *Cell Mol Life Sci* **75**, 3251–3267 (2018).
- 603 34. Demaria, M. C. *et al.* Tetraspanin CD53 Promotes Lymphocyte Recirculation by
604 Stabilizing L-Selectin Surface Expression. *iScience* **23**, (2020).

- 605 35. Xiao, H., Woods, E. C., Vukojcic, P. & Bertozzi, C. R. Precision glyocalyx editing as
606 a strategy for cancer immunotherapy. *Proceedings of the National Academy of*
607 *Sciences of the United States of America* **113**, 10304–9 (2016).
- 608 36. Linden, S. K., Sutton, P., Karlsson, N. G., Korolik, V. & McGuckin, M. A. Mucins in
609 the mucosal barrier to infection. *Mucosal Immunol* **1**, 183–197 (2008).
- 610 37. Park, S. *et al.* Mucins form a nanoscale physical barrier against immune cell attack.
611 *Biophysical Journal* **122**, 435a (2023).
- 612 38. Ragaller, F. *et al.* Studying macromolecular composition in cell-cell interfaces using
613 3D membrane reconstitution systems. 2025.11.01.686034 Preprint at
614 <https://doi.org/10.1101/2025.11.01.686034> (2025).
- 615 39. Jenkins, E. *et al.* Antigen discrimination by T cells relies on size-constrained
616 microvillar contact. *Nat Commun* **14**, 1611 (2023).
- 617 40. Chen, K. Y. *et al.* Trapping or slowing the diffusion of T cell receptors at close
618 contacts initiates T cell signaling. *Proc Natl Acad Sci U S A* **118**, e2024250118
619 (2021).
- 620 41. Schneider, F. *et al.* Statistical Analysis of Scanning Fluorescence Correlation
621 Spectroscopy Data Differentiates Free from Hindered Diffusion. *ACS Nano* **12**,
622 8540–8546 (2018).
- 623 42. Sych, T. *et al.* High-throughput measurement of the content and properties of nano-
624 sized bioparticles with single-particle profiler. *Nat Biotechnol* 1–4 (2023)
625 doi:10.1038/s41587-023-01825-5.
- 626